Akebia Therapeutics up 70% in the after hours is why you should consider buying biotechs and Tetraphase Pharmaceuticals down 79% is why many don’t.  Small-cap biotechs offer the biggest mispricing (opportunities) in the market; a promised land full of landmines.  A basket of biotechs and or the ETF’s (XBI, BBH) make more sense to me than a flyer with one.

fzorrilla@zorcapital.com   @Zortrades
This information is issued solely for informational and educational purposes and does not constitute an offer to sell or a solicitation of an offer to buy securities. None of the information contained in this blog constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. From time to time, the content creator or its affiliates may hold positions or other interests in securities mentioned in this blog. The stocks presented are not to be considered a recommendation to buy any stock. This material does not take into account your particular investment objectives. Investors should consult their own financial or investment adviser before trading or acting upon any information provided. Past performance is not indicative of future results.